Compositions and methods for identifying secretory antibody-bound microbes
The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.
1. A method of treating an inflammatory disease or disorder in a subject in need thereof, wherein a secretory antibody bound bacteria in the microbiota of the subject has been detected in a biological sample obtained from the subject, the method comprising administering to the subject a vaccine to diminish the number of at least one type of bacteria that is over-represented in the microbiota of the subject.
2. The method of claim 1 , wherein the microbiota of the subject is on or near a mucosal surface of the subject selected from the group consisting of the gastrointestinal tract, the respiratory tract, genitourinary tract and mammary gland.
3. The method of claim 1 , wherein the secretory antibody is at least one selected from the group consisting of IgA1, IgA2, and IgM.
4. The method of claim 1 , wherein the type of bacteria is at least one selected from the group consisting of Segmented Filamentous Bacteria (SFB), Heliobacter flexispira, Helicobacter , S24-7, Erysipelotrichaceae, Prevotellaceae, Eubacterium species, Eubacterium biforme, Eubacterium dolichum, Ruminococcus gnavus, Acidaminococcus, Actinomyces, Allobaculum species, Anaerostipes, Bacteroides species, Bacteroides fragilis, Bifidobacterium species, Bifidobacterium adolescentis, Blautia species, Blautia obeum, Blautia producta, Bulleidia species, Clostridium species, Clostridium perfringens, Collinsella aerofaciens, Coprococcus species, Coprococcus catus, Dialister species, Eggerthella lenta , Erysipelotrichaceae, Faecalibacterium prausnitzii, Haemophilus parainfluenzae, Lachnospiraceae species, Lactobacillus species, Lactobacillus mucosae, Lactobacillus reuteri, Lactobacillus zeae, Oscillospira species, Pediococcus species, Rikenellaceae, Roseburia, Roseburia faecis, Ruminococcaceae species, Ruminococcus species, Ruminococcus bromii , SMB53, Streptococcus species, Streptococcus luteciae, Sutterella species, Turicibacter species, UC Clostridiales , UC Erysipelotrichaceae , UC Ruminococcaceae, Veillonella species, Veillonella dispar , and Weissella species.
5. The method of claim 4 , wherein the bacteria from the bacterial family Prevotellaceae is a bacteria from the bacterial genera of Paraprevotella or Prevotella.
6. The method of claim 1 , wherein the inflammatory disease or disorder is at least one inflammatory disease or disorder selected from the group consisting of inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
7. The method of claim 1 , wherein the vaccine induces an immune response directed against the secretory antibody-bound bacteria present in the microbiota of the subject.
8. The method of claim 1 , wherein the method further comprises administering to the subject at least one probiotic to increase the number of at least one type of bacteria under-represented in the microbiota of the subject.
9. The method of claim 1 , wherein the at least one type of bacteria is selected from the group consisting of Segmented Filamentous Bacteria (SFB), Heliobacter flexispira, Faecalibacterium prausnitzii, Coprococcus species, Weissella species, Bulleidia species, Allobaculum species, and Pediococcus species.
10. The method of claim 1 , wherein the secretory antibody bound bacteria in the microbiota of the subject is detected by
a. isolating a secretory antibody-bound bacteria from the subject's biological sample,
b. amplifying bacterial nucleic acid from the secretory antibody-bound bacteria so isolated,
c. determining the sequences of the amplicons so amplified,
d. identifying the type of antibody-bound bacteria present in the subject's biological sample by identifying nucleic acid sequences that are indicative of particular types of bacteria.
11. The method of claim 10 , wherein the biological sample is at least one of a fecal sample, a mucus sample, a sputum sample, and a breast milk sample.
12. The method of claim 10 , wherein the bacterial nucleic acid is 16S rRNA.